###begin article-title 0
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (Activated Thrombin-activable Fibrinolysis Inhibitor), and Platelets*
###end article-title 0
###begin p 1
###xml 50 57 <span type="species:ncbi:28980">Redwood</span>
Present address: Maxygen Inc., 515 Galveston Dr., Redwood City, CA 94063.
###end p 1
###begin p 2
###xml 149 176 149 176 <email xmlns:xlink="http://www.w3.org/1999/xlink">lawrence.leung@stanford.edu</email>
 To whom corresponding should be addressed: VA Palo Alto Health Care System, 3801 Miranda Ave. (11), Palo Alto, CA 94304. Fax: 650-736-0974; E-mail: lawrence.leung@stanford.edu. 
###end p 2
###begin p 3
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 3
###begin p 4
 applies to Author Choice Articles
###end p 4
###begin p 5
###xml 560 561 560 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 680 681 680 681 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Chemerin is a potent chemoattractant for cells expressing the serpentine receptor CMKLR1 (chemokine-like receptor 1), such as plasmacytoid dendritic cells and tissue macrophages. The bioactivity of chemerin is post-translationally regulated; the attractant circulates in blood in a relatively inactive form (prochemerin) and is activated by carboxyl-terminal proteolytic cleavage. We discovered that plasma carboxypeptidase N (CPN) and B (CPB or activated thrombin-activable fibrinolysis inhibitor, TAFIa) enhanced the bioactivity of 10-mer chemerin peptide NH2-YFPGQFAFSK-COOH by removing the carboxyl-terminal lysine (K). Sequential cleavages of either a prochemerin peptide (NH2-YFPGQFAFSKALPRS-COOH) or recombinant full-length prochemerin by plasmin and CPN/CPB substantially increased their chemotactic activities. Endogenous CPN present in circulating plasma enhanced the activity of plasmin-cleaved prochemerin. In addition, we discovered that platelets store chemerin protein and release it upon stimulation. Thus circulating CPN/CPB and platelets may potentially contribute to regulating the bioactivity of leukocyte chemoattractant chemerin, and further extend the molecular link between blood coagulation/fibrinolysis and CMKLR1-mediated immune responses.
###end p 5
###begin p 6
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 6
###begin p 7
###xml 49 78 49 78 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 86 97 86 97 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">RO1 HL57530</grant-num>
###xml 113 120 113 120 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">AI59625</grant-num>
###xml 122 130 122 130 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">AI057229</grant-num>
###xml 136 143 136 143 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">DK56339</grant-num>
###xml 297 310 297 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported, in whole or in part, by National Institutes of Health Grants RO1 HL57530 (to L. L.) and AI59625, AI057229, and DK56339 (to E. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 7
###begin p 8
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 556 557 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">3</xref>
###xml 730 731 730 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 732 733 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 1076 1077 1076 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 1079 1080 1079 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 1082 1083 1082 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 265 270 <span type="species:ncbi:9606">human</span>
###xml 648 653 <span type="species:ncbi:9606">human</span>
Chemerin is a recently discovered chemoattractant molecule that is predicted to share structural similarity with cystatins (cysteine protease inhibitors) and cathelicidin precursors (antibacterial peptides) (1). Chemerin is present in circulating blood and several human inflammatory fluids (1). Even though chemerin is not similar to CXC and CC chemokines based on primary amino acid sequence, it functions like a chemokine in that it induces leukocyte migration and intracellular calcium mobilization. Chemerin receptor chemokine-like receptor 1 (CMKLR1,3 also named ChemR23) is a G protein-coupled receptor specifically expressed by circulating human plasmacytoid dendritic cells, natural killer cells, and tissue macrophages (1-5). In their capacity as antigen-presenting cells, plasmacytoid dendritic cells and macrophages can influence the activation of many other cell types, including monocytes, myeloid dendritic cells, B cells, T cells, and natural killer cells; thus chemerin appears to be an important chemoattractant in both innate and adaptive immune responses (2, 6, 7).
###end p 8
###begin p 9
###xml 110 111 98 99 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 114 115 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 304 305 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 307 308 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 457 478 445 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 552 553 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 625 626 613 614 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 829 830 817 818 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1018 1019 1006 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 1021 1023 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 457 478 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Chemerin circulates in blood in an inactive prochemerin form at low nanomolar concentrations (approximately3 nm) (4). Its chemotactic activity is released following proteolytic cleavage of its carboxyl-terminal amino acids by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades (4, 8). These include factor XIIa, VIIa, plasmin, neutrophil elastase, and mast cell tryptase. Of interest, staphopain B, a cysteine protease secreted by Staphylococcus aureus, also cleaves prochemerin and converts it into a potent chemoattractant (9). Interestingly, the cleavage sites in the labile carboxyl terminus (NH2-YFPGQFAFSKALPRS-COOH) are not conserved, and the cleavage products generated by chemerin-activating proteases display different potencies in bioactivity assays. Based on synthetic peptides, the 9-mer NH2-YFPGQFAFS-COOH is the most active, but it is still not as active as intact cleaved chemerin protein, indicating that the amino-terminal part of chemerin is required for maximal activity (4, 10).
###end p 9
###begin p 10
###xml 295 296 295 296 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 549 550 549 550 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 937 939 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 1094 1096 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 1097 1099 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 1428 1429 1410 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 1598 1600 1580 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 1602 1604 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
Plasma carboxypeptidases CPN and CPB cleave the basic amino acids arginine or lysine from the carboxyl terminus of proteins or peptides such as bradykinin and complement proteins C3a and C5a. CPN is a constitutively active zinc metalloprotease present in plasma at a concentration of about 100 nm and is considered the major anaphylatoxins inhibitor (11), generating inactive "desArg" forms of C3a and C5a. In contrast, CPB exists in plasma as a proenzyme, proCPB, or thrombin-activable fibrinolysis inhibitor (TAFI) at a concentration of about 50 nm and is activated by thrombin in complex with thrombomodulin on the vascular endothelial surface. CPB inhibits fibrin degradation by removing carboxyl-terminal lysines from partially digested fibrin, which prevents further incorporation of fibrinolytic plasminogen and tissue plasminogen activator (12, 13). CPB is thermolabile and has a half-life of approximately15 min at 37 degreesC (14). We have shown that CPB also has broad substrate reactivity and is able to cleave and inactivate bradykinin, C3a, C5a, and thrombin-cleaved osteopontin (15-17). CPN and CPB may play complementary roles, with the former being constitutively active and capable of regulating systemic anaphylatoxins, and the latter activated locally at sites of vascular injury to provide site-specific anti-inflammatory control. Peptidases can also modulate the biological activity of certain chemokines (4). For example, dipeptidyl peptidase (DPP-IV/CD26), a serine protease, inactivates CXCL9, CXCL10, CXCL11, and CXCL12 by cleaving these chemokines in the amino terminus (18, 19).
###end p 10
###begin p 11
###xml 441 443 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 445 447 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 641 643 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 645 647 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 851 853 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 754 782 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Platelets store a variety of potent cytokines and chemokines within alpha-granules that are released upon cell activation. Platelet degranulation products, particularly the leukocyte chemoattractants, which include CXCL4 (platelet factor 4), beta-thromboglobulin, CCL5 (RANTES), CCL7 (monocyte chemotactic protein 3), and CXCL12 (stromal-derived factor 1), may contribute to host defense and also play a role in pathophysiologic conditions (20, 21). For example, platelet factor 4 forms complexes with heparin in blood or some glycosaminoglycans on platelet surfaces to form the major antigen implicated in heparin-induced thrombocytopenia (22, 23). Platelets not only store CXCL12 but also express its receptor CXCR4, a coreceptor for cellular entry of human immunodeficiency virus, type 1, suggesting that platelets may be involved in host defense (24).
###end p 11
###begin p 12
In this study, we found that plasma CPN or CPB can function in concert with plasmin to elicit and augment the chemotactic activity of prochemerin. Furthermore, we show that platelets could store and release partially active chemerin upon activation. Thus circulating CPN/CPB and platelets may contribute to regulating the bioactivity of leukocyte chemoattractant chemerin and further extend the molecular link between blood coagulation/fibrinolysis and CMKLR1-mediated immune responses.
###end p 12
###begin title 13
EXPERIMENTAL PROCEDURES
###end title 13
###begin p 14
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Materials</italic>
###xml 36 42 36 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">21&#8211;157</sup>
###xml 225 232 225 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;157</sup>
###xml 263 270 263 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;158</sup>
###xml 310 317 310 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;163</sup>
###xml 478 480 474 476 <sc xmlns:xlink="http://www.w3.org/1999/xlink">dl</sc>
###xml 798 799 794 795 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 813 814 809 810 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 822 823 818 819 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 55 59 <span type="species:ncbi:9925">goat</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 120 124 <span type="species:ncbi:9925">goat</span>
###xml 130 135 <span type="species:ncbi:9606">human</span>
###xml 378 383 <span type="species:ncbi:9606">Human</span>
###xml 640 645 <span type="species:ncbi:9606">Human</span>
###xml 883 889 <span type="species:ncbi:9913">bovine</span>
###xml 921 926 <span type="species:ncbi:9606">Human</span>
Materials-Recombinant human chemerin21-157, polyclonal goat anti-human chemerin antibodies, and biotinylated polyclonal goat anti-human antibodies were from R & D Systems (Minneapolis, MN). Peptides 9-mer, YFPGQFAFS (chemerin149-157); 10-mer, YFPGQFAFSK (chemerin149-158); and 15-mer, YFPGQFAFSKALPRS (chemerin149-163) were synthesized by Elim Biopharmaceuticals (Hayward, CA). Human plasmin and alpha-thrombin were purchased from Hematologic Technologies (Essex Junction, VT). dl-2-Mercaptomethyl-3 guanidinoethylthiopropanoic acid (MGTA) was obtained from Calbiochem (La Jolla, CA). Collagen and ADP were from Chrono-log (Havertown, PA). Human plasma-derived CPB (TAFIa) and a CPB activity kit were from American Diagnostica (Stamford, CT). Thrombin receptor-activating peptide (SFLLRN peptide), d-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone (PPACK), heparin-agarose, and bovine serum albumin were from Sigma. Human soluble thrombomodulin and recombinant CPN were kind gifts from Drs. John Moser and Mariko Nagashima (Berlex Biosciences, Richmond, CA). Hep3B and MEG-01 cells were from the American Type Culture Collection.
###end p 14
###begin p 15
###xml 0 38 0 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Preparation of Recombinant Prochemerin</italic>
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 154 155 154 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 295 296 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 319 326 319 326 <underline xmlns:xlink="http://www.w3.org/1999/xlink">PHHHHHH</underline>
###xml 662 663 655 656 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Preparation of Recombinant Prochemerin-Recombinant prochemerin was purified as previously published (8). Briefly, prochemerin with a carboxyl-terminal His6 tag was cloned into pACGP67 (BD Biosciences) and transfected into Sf-9 cells. The mature prochemerin protein has the amino acid sequence NH2-ADPELTEAQ...FAFSKALPRSPHHHHHH-COOH, where the underlined residues are not native. After viral amplification, prochemerin was expressed by adding high titer virus to shaker flasks containing Hi-5 insect cells in Ex-cell 420 medium (JRH Biosciences). After incubation for 2-3 days at 27.5 degreesC, the supernatant was harvested by centrifugation, filtered to 0.22 mum, and concentrated at 4 degreesC using a tangential flow concentrator with a 3-kDa cut-off filter (Filtron). Prochemerin was purified by nickel-Sepharose affinity chromatography (American Biosciences) and C-18 reverse phase HPLC (Vydac). The protein was lyophilized and checked for purity using electrospray mass spectrometry.
###end p 15
###begin p 16
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tissue Culture</italic>
###xml 15 21 <span type="species:ncbi:10090">Murine</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 189 195 <span type="species:ncbi:9913">bovine</span>
Tissue Culture-Murine pre-B lymphoma L1.2 cells were stably transfected with human CMKLR1 or empty vector pcDNA3 (Invitrogen) and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1 mg/ml geneticin (Invitrogen).
###end p 16
###begin p 17
###xml 0 35 0 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Vitro Transwell Chemotaxis Assay</italic>
###xml 156 157 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 176 182 <span type="species:ncbi:9913">bovine</span>
In Vitro Transwell Chemotaxis Assay-24-well plates with 5-mum pore size Transwell inserts (Costar) were used for the chemotaxis assays. 200 mul of cells (106 cells/ml) in 0.3% bovine serum albumin/Hank's solution were added to the top well, and test samples were added to the bottom well in 500 mul of solution. The cells that migrated to the lower chamber after 3 h at 37 degreesC were counted by flow cytometry, and the results are reported as cells/ml in the lower chamber.
###end p 17
###begin p 18
###xml 0 97 0 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Preparation of Platelet-rich Plasma, Platelet-poor Plasma, Washed Platelets, and Platelet Lysates</italic>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 388 389 388 389 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 402 403 402 403 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 413 414 413 414 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 659 660 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
Preparation of Platelet-rich Plasma, Platelet-poor Plasma, Washed Platelets, and Platelet Lysates-Blood was drawn into tubes containing 3.8% sodium citrate (9:1 v/v) and platelet-rich plasma (PRP) prepared following standard procedure (25). Platelet-poor plasma was prepared by spinning the PRP at 1200 x g for 10 min at room temperature. The platelets were washed with PIPES buffer (25 mm PIPES, 137 mm NaCl, 4 mm KCl, and 0.1% glucose) at pH 6.4 as previously described (25). Platelet lysates were obtained by lysing washed platelets with radioimmune precipitation assay lysis buffer (Upstate, NY) with protease inhibitors. The mixture was spun at 10,000 x g, and the supernatant protein concentration was determined by Bradford protein assay.
###end p 18
###begin p 19
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Reverse Transcription (RT)-PCR</italic>
###xml 59 64 <span type="species:ncbi:9606">human</span>
Reverse Transcription (RT)-PCR-Total RNA was prepared from human washed platelets and Hep3B and MEG-01 cells by using TRIzol reagent. Total RNA (approximately1 mug) was converted to cDNAs using the oligo(dT) primer and Superscript II enzyme (Invitrogen). The specific primers used for cloning a 229-bp chemerin fragment were GAAGAAACCCGAGTGCAAAG (forward) and CTTGGAGAAGGCGAACTGTC (reverse) (the annealing temperature was 57 degreesC, 35 cycles).
###end p 19
###begin p 20
###xml 0 43 0 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPLC Analysis of Chemerin Peptides Cleavage</italic>
###xml 146 147 144 145 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 189 190 187 188 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 423 424 414 415 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 458 459 448 449 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 562 563 545 546 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 582 583 565 566 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
HPLC Analysis of Chemerin Peptides Cleavage-To evaluate the efficiency of synthetic chemerin 10-mer cleavage by CPN or CPB, 50 mul of 10-mer (1 mum) was treated with either CPN or CPB (30 nm) for 30 min at 37 degreesC, and the reaction mixtures were loaded onto a Waters C18 (4.6 x 150 mm) column and separated with a 0-35% acetonitrile gradient in 0.1% trifluoroacetic acid (v/v) by HPLC. For 15-mer cleavage, 15-mer (1 mum) was incubated with plasmin (1 mum) at 37degrees for 30 min; the reaction was then terminated by PPACK (serine protease inhibitor) (10 mum). CPN or CPB (30 nm) was added and incubated for 30 min at 37 degreesC. 40 mul of each reaction mixture (15-mer, 15-mer plus plasmin, 15-mer plus plasmin and CPN/CPB) was analyzed by reverse phase HPLC as described above.
###end p 20
###begin p 21
###xml 0 73 0 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kinetic Analysis of Hydrolysis of 10-mer Chemerin Peptides by CPB and CPN</italic>
###xml 127 128 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 126 128 126 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 134 137 134 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 266 267 265 266 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 295 296 294 295 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 307 308 306 307 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 546 547 539 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 545 547 538 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 552 553 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 553 556 546 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 775 777 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
Kinetic Analysis of Hydrolysis of 10-mer Chemerin Peptides by CPB and CPN-Michaelis-Menten kinetics was used to determine the Km and kcat for the hydrolysis of 10-mer peptide (YFPGQFAFSK) by CPB and CPN. The concentrations of 10-mer peptides ranged from 20 to 320 mum and were digested with 50 nm CPB or 5 nm CPN for 5 min at 37 degreesC in assay buffer. The reactions were stopped by boiling for 5 min. Cleaved peptide was resolved by HPLC, and the nmol of peptide generated was determined from the peak area of cleaved peptide. The values for Km and kcat were determined by plotting the initial velocities of cleavage against the different substrate concentrations and then fitting to the Michaelis-Menten equation by nonlinear regression analysis as previously described (15). The experiments were performed in duplicate, and the data were pooled for analysis.
###end p 21
###begin p 22
###xml 0 19 0 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CPB Activity Assays</italic>
###xml 40 41 39 40 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 56 57 55 56 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
CPB Activity Assays-100 mul of CPN (10 nm) and CPB (15 nm) were added to a 96-well plate in the presence or absence of MGTA at the indicated concentrations. 50 mul of chromogenic CPB (TAFIa) substrate was used in each well as described in the Actichrome CPB kit. Activated CPB (TAFIa) ranging from 0.125 to 2 mug/ml was used to construct the standard curve. All of the tests were performed in duplicate. The plate was placed in an ELISA plate reader at 37 degreesC with constant mixing, and the absorbance at 420 nm was read 30 min after sample addition.
###end p 22
###begin p 23
###xml 0 42 0 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Development of Sandwich ELISA for Chemerin</italic>
###xml 54 58 <span type="species:ncbi:9925">goat</span>
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 179 183 <span type="species:ncbi:9925">goat</span>
###xml 189 194 <span type="species:ncbi:9606">human</span>
###xml 232 243 <span type="species:ncbi:3704">horseradish</span>
Development of Sandwich ELISA for Chemerin-Polyclonal goat anti-human chemerin antibodies were used to coat 96-well plates at a concentration of 4 mug/ml. Biotinylated polyclonal goat anti-human chemerin antibodies (0.2 mug/ml) and horseradish peroxidase-labeled streptavidin was used to detect bound chemerin protein. The lower limit of detection of chemerin in this assay was approximately0.5 ng/ml. For the determination of chemerin levels in plasma, the samples were diluted 10-fold before assay.
###end p 23
###begin p 24
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mass Spectrometry</italic>
Mass Spectrometry-MALDI-TOF mass spectrometry was performed by the Stanford Protein and Nucleic Acid Core Facility.
###end p 24
###begin p 25
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Statistical Analyses</italic>
###xml 124 125 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 183 184 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Statistical Analyses-The data are expressed as the means +/- S.D., and statistical evaluation was performed using Student's t test. Differences were considered to be significant when p < 0.05 (*) or 0.005 (**).
###end p 25
###begin title 26
RESULTS
###end title 26
###begin p 27
###xml 0 97 0 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CPN and CPB Up-regulate Chemerin 10-mer Activity by Removing the Carboxyl-terminal Lysine Residue</italic>
###xml 154 161 154 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;157</sup>
###xml 251 252 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 245 252 245 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 296 297 296 297 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 419 426 419 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;158</sup>
###xml 500 501 499 500 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 523 524 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 517 524 516 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 655 656 654 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 649 656 648 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 693 694 692 693 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 753 754 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 747 754 746 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 1168 1169 1167 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1162 1169 1161 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 1220 1221 1219 1220 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1351 1352 1350 1351 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1467 1468 1454 1455 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1484 1486 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 1488 1490 1475 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 212 217 <span type="species:ncbi:9606">human</span>
CPN and CPB Up-regulate Chemerin 10-mer Activity by Removing the Carboxyl-terminal Lysine Residue-The synthetic 9-mer chemerin peptide YFPGQFAFS (chemerin149-157) induced substantial, dose-dependent migration of human CMKLR1-L1.2 transfectants (Fig. 1A) with a peak response occurring at 10-100 nm. Empty vector transfected controls did not migrate to the 9-mer (data not shown), The 10-mer peptide YFPGQFAFSK (chemerin149-158) did not induce any significant CMKLR1-dependent chemotaxis even at 10 mum concentration (Fig. 1A). Treatment of the 10-mer peptide with CPN or CPB, however, substantially enhanced the chemotactic activity of the peptide (Fig. 1B). CPN and CPB alone (tested at 100 nm) did not induce CMKLR1/L1.2 transfectant migration (Fig. 1B). We analyzed the mixtures of 10-mer treated with either CPN or CPB by HPLC and found that the 10-mer/CPN mixture had a major peak with a retention time of 28.25 min, which is almost identical to that of the purified 9-mer (28.26 min), and different from the 10-mer (25.90 min). For the 10-mer treated with CPB, we detected two major fractions corresponding to the 10-mer (25.90 min) and 9-mer (28.28 min) (Fig. 1C). The efficiency of 10-mer cleavage by CPB at 30 nm was about 60%, likely because CPB is thermolabile under the experimental conditions used. In this work, CPN was also used at 30 nm to compare with CPB enzymatic activity. Of note, the plasma levels of proCPB and CPN are approximately50 and 100 nm, respectively (11, 14).
###end p 27
###begin p 28
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 9 99 9 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CPN and CPB up-regulate chemerin 10-mer activity by removing the carboxyl-terminal lysine.</bold>
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 105 116 105 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, in vitro</italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 232 233 232 233 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 247 248 247 248 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 301 302 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 405 406 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 413 414 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 519 520 509 510 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 562 563 552 553 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 9 641 9 625 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><bold>CPN and CPB up-regulate chemerin 10-mer activity by removing the carboxyl-terminal lysine.</bold><italic>A</italic> and <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 transfectants to synthetic 9- and 10-mer chemerin peptides (<italic>A</italic>) and to CPN (30 n<sc>m</sc>) or CPB (30 n<sc>m</sc>)-treated 10-mer peptides at 37 &#176;C for 30 min (<italic>B</italic>). The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). <italic>C</italic>, HPLC analysis of the chemerin 10-mer cleavage products generated by CPN and CPB. 50 &#956;l of 10-mer (1 &#956;<sc>m</sc>) was treated with either CPN or CPB (30 n<sc>m</sc>) for 30 min at 37 &#176;C, and the reaction mixtures were separated by HPLC.</p>
###xml 9 641 9 625 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29"><bold>CPN and CPB up-regulate chemerin 10-mer activity by removing the carboxyl-terminal lysine.</bold><italic>A</italic> and <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 transfectants to synthetic 9- and 10-mer chemerin peptides (<italic>A</italic>) and to CPN (30 n<sc>m</sc>) or CPB (30 n<sc>m</sc>)-treated 10-mer peptides at 37 &#176;C for 30 min (<italic>B</italic>). The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). <italic>C</italic>, HPLC analysis of the chemerin 10-mer cleavage products generated by CPN and CPB. 50 &#956;l of 10-mer (1 &#956;<sc>m</sc>) was treated with either CPN or CPB (30 n<sc>m</sc>) for 30 min at 37 &#176;C, and the reaction mixtures were separated by HPLC.</p></caption>
###xml 641 641 625 625 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0070963680001"/>
###xml 0 641 0 625 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="29"><bold>CPN and CPB up-regulate chemerin 10-mer activity by removing the carboxyl-terminal lysine.</bold><italic>A</italic> and <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 transfectants to synthetic 9- and 10-mer chemerin peptides (<italic>A</italic>) and to CPN (30 n<sc>m</sc>) or CPB (30 n<sc>m</sc>)-treated 10-mer peptides at 37 &#176;C for 30 min (<italic>B</italic>). The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). <italic>C</italic>, HPLC analysis of the chemerin 10-mer cleavage products generated by CPN and CPB. 50 &#956;l of 10-mer (1 &#956;<sc>m</sc>) was treated with either CPN or CPB (30 n<sc>m</sc>) for 30 min at 37 &#176;C, and the reaction mixtures were separated by HPLC.</p></caption><graphic xlink:href="zbc0070963680001"/></fig>
FIGURE 1.CPN and CPB up-regulate chemerin 10-mer activity by removing the carboxyl-terminal lysine.A and B, in vitro transwell chemotaxis of CMKLR1/L1.2 transfectants to synthetic 9- and 10-mer chemerin peptides (A) and to CPN (30 nm) or CPB (30 nm)-treated 10-mer peptides at 37 degreesC for 30 min (B). The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). C, HPLC analysis of the chemerin 10-mer cleavage products generated by CPN and CPB. 50 mul of 10-mer (1 mum) was treated with either CPN or CPB (30 nm) for 30 min at 37 degreesC, and the reaction mixtures were separated by HPLC.
###end p 28
###begin p 29
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CPN and CPB up-regulate chemerin 10-mer activity by removing the carboxyl-terminal lysine.</bold>
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 96 107 96 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, in vitro</italic>
###xml 204 205 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 223 224 223 224 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 238 239 238 239 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 292 293 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 396 397 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 404 405 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 510 511 500 501 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 553 554 543 544 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
CPN and CPB up-regulate chemerin 10-mer activity by removing the carboxyl-terminal lysine.A and B, in vitro transwell chemotaxis of CMKLR1/L1.2 transfectants to synthetic 9- and 10-mer chemerin peptides (A) and to CPN (30 nm) or CPB (30 nm)-treated 10-mer peptides at 37 degreesC for 30 min (B). The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). C, HPLC analysis of the chemerin 10-mer cleavage products generated by CPN and CPB. 50 mul of 10-mer (1 mum) was treated with either CPN or CPB (30 nm) for 30 min at 37 degreesC, and the reaction mixtures were separated by HPLC.
###end p 29
###begin p 30
###xml 86 93 86 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;158</sup>
###xml 0 109 0 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Determination of the Kinetic Parameters for the Hydrolysis of 10-mer Peptide (Chemerin<sup>149&#8211;158</sup>) by CPB and CPN</italic>
###xml 136 143 136 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;158</sup>
###xml 171 172 171 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 170 172 170 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 190 191 187 188 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 194 195 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 195 198 192 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 213 215 208 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 222 223 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 223 226 218 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 228 229 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 227 229 222 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 239 240 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 240 241 235 236 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 241 243 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 245 247 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 250 257 245 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 290 297 285 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;158</sup>
###xml 322 323 316 317 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 360 361 354 355 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 371 372 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 372 375 366 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 377 378 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 376 378 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 466 471 460 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">66&#8211;74</sup>
###xml 476 481 470 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">69&#8211;77</sup>
###xml 526 531 516 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">77&#8211;85</sup>
###xml 548 549 538 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 549 552 539 542 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 554 555 544 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 553 555 543 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 593 594 583 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 594 595 584 585 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 595 597 585 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
###xml 599 601 589 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;1</sup>
Determination of the Kinetic Parameters for the Hydrolysis of 10-mer Peptide (Chemerin149-158) by CPB and CPN-The hydrolysis of chemerin149-158 by CPB gave estimates for Km (122.8 +/- 6.4 mum), kcat (2.7 +/- 0.1 s-1), and kcat/Km (2.2 x 104m-1 s-1) (Table 1). The concentrations of chemerin149-158 ranged from 20 to 320 mum, and chemerin was digested with 50 nm CPB. The kcat/Km for chemerin cleavage was about 10-fold less efficient compared with bradykinin and C5a66-74, C3a69-77 but comparable with fibrinopeptide gamma-Lys77-85. Meanwhile, the kcat/Km of 10-mer cleavage by CPN is 4.7 x 105m-1 s-1, which is about 20-fold faster than CPB, and is about 20-fold faster than bradykinin and C5a peptide but similar to that of C3a peptide.
###end p 30
###begin p 31
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 1</label>
###xml 7 60 7 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hydrolysis of chemerin 10-mer peptides by CPB and CPN</bold>
###xml 7 60 7 60 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><bold>Hydrolysis of chemerin 10-mer peptides by CPB and CPN</bold></p>
###xml 103 104 102 103 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 197 198 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 196 201 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub>, k</italic>
###xml 201 204 200 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 210 211 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 211 214 210 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 216 217 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 215 217 214 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 375 377 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 60 379 60 367 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Chemerin peptides ranging from 20 to 320 &#956;<sc>m</sc> were digested with CPB or CPN as described under &#8220;Experimental Procedures.&#8221; The values for <italic>K<sub>m</sub>, k</italic><sub>cat</sub>, and <italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic> were compared with those obtained from CPB and CPN cleavages of peptides derived from bradykinin, C5a, C3a, and fibrinopeptides (FB) &#945;, &#946;, and &#947; (<xref ref-type="bibr" rid="ref15">15</xref>).</p>
###xml 7 379 7 367 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><bold>Hydrolysis of chemerin 10-mer peptides by CPB and CPN</bold></p><p textid="33">Chemerin peptides ranging from 20 to 320 &#956;<sc>m</sc> were digested with CPB or CPN as described under &#8220;Experimental Procedures.&#8221; The values for <italic>K<sub>m</sub>, k</italic><sub>cat</sub>, and <italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic> were compared with those obtained from CPB and CPN cleavages of peptides derived from bradykinin, C5a, C3a, and fibrinopeptides (FB) &#945;, &#946;, and &#947; (<xref ref-type="bibr" rid="ref15">15</xref>).</p></caption>
###xml 379 388 367 376 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Substrate</bold>
###xml 379 388 367 376 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Substrate</bold></th>
###xml 388 394 376 382 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Enzyme</bold>
###xml 388 394 376 382 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Enzyme</bold></th>
###xml 395 396 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 394 396 382 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 394 396 382 384 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>K<sub>m</sub></italic></bold>
###xml 394 396 382 384 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th>
###xml 396 397 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 397 400 385 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 396 400 384 388 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>k</italic><sub>cat</sub></bold>
###xml 396 400 384 388 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub></bold></th>
###xml 400 401 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 401 404 389 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 406 407 394 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 405 407 393 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 400 407 388 395 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic></bold>
###xml 400 407 388 395 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic></bold></th>
###xml 379 407 367 395 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold>Substrate</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Enzyme</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic></bold></th></tr>
###xml 379 407 367 395 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Substrate</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Enzyme</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic></bold></th></tr></thead>
###xml 407 407 395 395 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 407 407 395 395 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 410 411 397 398 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 410 411 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sc>m</sc></italic>
###xml 407 411 395 398 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td>
###xml 412 414 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 411 414 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s<sup>-1</sup></italic>
###xml 411 414 398 401 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>s<sup>-1</sup></italic></td>
###xml 414 415 401 402 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 415 417 402 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 419 421 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 414 421 401 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sc>m</sc><sup>-1</sup> s<sup>-1</sup></italic>
###xml 414 421 401 408 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic><sc>m</sc><sup>-1</sup> s<sup>-1</sup></italic></td>
###xml 407 421 395 408 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>s<sup>-1</sup></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic><sc>m</sc><sup>-1</sup> s<sup>-1</sup></italic></td></tr>
###xml 421 431 408 418 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td>
###xml 431 436 418 423 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPB </td>
###xml 436 451 423 436 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 122.8 &#177; 6.4 </td>
###xml 451 464 436 447 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.7 &#177; 0.1 </td>
###xml 473 474 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 464 474 447 457 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.2 &#215; 10<sup>4</sup></td>
###xml 421 474 408 457 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 122.8 &#177; 6.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.7 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.2 &#215; 10<sup>4</sup></td></tr>
###xml 474 486 457 469 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td>
###xml 486 491 469 474 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPB </td>
###xml 491 505 474 486 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 70.6 &#177; 4.8 </td>
###xml 505 519 486 498 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 19.7 &#177; 4.8 </td>
###xml 528 529 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 519 529 498 508 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.8 &#215; 10<sup>5</sup></td>
###xml 474 529 457 508 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 70.6 &#177; 4.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 19.7 &#177; 4.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.8 &#215; 10<sup>5</sup></td></tr>
###xml 533 538 512 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">66-74</sup>
###xml 529 538 508 517 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td>
###xml 538 543 517 522 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPB </td>
###xml 543 559 522 536 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 219.0 &#177; 16.2 </td>
###xml 559 573 536 548 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 29.5 &#177; 0.7 </td>
###xml 582 583 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 573 583 548 558 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.3 &#215; 10<sup>5</sup></td>
###xml 529 583 508 558 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 219.0 &#177; 16.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 29.5 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.3 &#215; 10<sup>5</sup></td></tr>
###xml 587 592 562 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">69-77</sup>
###xml 583 592 558 567 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td>
###xml 592 597 567 572 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPB </td>
###xml 597 611 572 584 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 35.9 &#177; 6.6 </td>
###xml 611 624 584 595 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 8.4 &#177; 0.6 </td>
###xml 633 634 604 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 624 634 595 605 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.3 &#215; 10<sup>5</sup></td>
###xml 583 634 558 605 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 35.9 &#177; 6.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 8.4 &#177; 0.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.3 &#215; 10<sup>5</sup></td></tr>
###xml 646 652 613 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">96-104</sup>
###xml 634 652 605 619 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td>
###xml 652 657 619 624 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPB </td>
###xml 657 673 624 638 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 361.4 &#177; 69.2 </td>
###xml 673 686 638 649 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#177; 0.1 </td>
###xml 695 696 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 686 696 649 659 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 4.2 &#215; 10<sup>3</sup></td>
###xml 634 696 605 659 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 361.4 &#177; 69.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.2 &#215; 10<sup>3</sup></td></tr>
###xml 707 714 667 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125-133</sup>
###xml 696 714 659 674 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td>
###xml 714 719 674 679 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPB </td>
###xml 719 733 679 691 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 14.3 &#177; 0.7 </td>
###xml 733 747 691 703 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 13.6 &#177; 0.2 </td>
###xml 756 757 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 747 757 703 713 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 9.5 &#215; 10<sup>5</sup></td>
###xml 696 757 659 713 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 14.3 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.6 &#177; 0.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.5 &#215; 10<sup>5</sup></td></tr>
###xml 769 774 721 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink">54-62</sup>
###xml 757 774 713 726 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td>
###xml 774 779 726 731 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPB </td>
###xml 779 793 731 743 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 34.0 &#177; 4.1 </td>
###xml 793 806 743 754 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.6 &#177; 0.1 </td>
###xml 815 816 763 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 806 816 754 764 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 7.6 &#215; 10<sup>4</sup></td>
###xml 757 816 713 764 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 34.0 &#177; 4.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.6 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.6 &#215; 10<sup>4</sup></td></tr>
###xml 828 833 772 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">77-85</sup>
###xml 816 833 764 777 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td>
###xml 833 838 777 782 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPB </td>
###xml 838 854 782 796 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 238.9 &#177; 24.2 </td>
###xml 854 867 796 807 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 5.9 &#177; 0.3 </td>
###xml 876 877 816 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 867 877 807 817 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.5 &#215; 10<sup>4</sup></td>
###xml 816 877 764 817 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 238.9 &#177; 24.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.9 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.5 &#215; 10<sup>4</sup></td></tr>
###xml 877 887 817 827 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td>
###xml 887 892 827 832 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPN </td>
###xml 892 908 832 846 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 170.6 &#177; 27.2 </td>
###xml 908 923 846 859 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 80.35 &#177; 5.0 </td>
###xml 932 933 868 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 923 933 859 869 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 4.7 &#215; 10<sup>5</sup></td>
###xml 877 933 817 869 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 170.6 &#177; 27.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 80.35 &#177; 5.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.7 &#215; 10<sup>5</sup></td></tr>
###xml 933 945 869 881 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td>
###xml 945 950 881 886 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPN </td>
###xml 950 966 886 900 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 302.7 &#177; 29.1 </td>
###xml 966 979 900 911 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 9.1 &#177; 0.2 </td>
###xml 988 989 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 979 989 911 921 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 3.0 &#215; 10<sup>4</sup></td>
###xml 933 989 869 921 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 302.7 &#177; 29.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.1 &#177; 0.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.0 &#215; 10<sup>4</sup></td></tr>
###xml 993 998 925 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink">66-74</sup>
###xml 989 998 921 930 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td>
###xml 998 1003 930 935 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPN </td>
###xml 1003 1019 935 949 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 602.2 &#177; 74.3 </td>
###xml 1019 1032 949 960 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 9.3 &#177; 0.4 </td>
###xml 1041 1042 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 1032 1042 960 970 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#215; 10<sup>4</sup></td>
###xml 989 1042 921 970 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 602.2 &#177; 74.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.3 &#177; 0.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#215; 10<sup>4</sup></td></tr>
###xml 1046 1051 974 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink">69-77</sup>
###xml 1042 1051 970 979 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td>
###xml 1051 1056 979 984 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPN </td>
###xml 1056 1071 984 997 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 77.1 &#177; 11.2 </td>
###xml 1071 1085 997 1009 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 57.9 &#177; 2.1 </td>
###xml 1094 1095 1018 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1085 1095 1009 1019 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 7.5 &#215; 10<sup>5</sup></td>
###xml 1042 1095 970 1019 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 77.1 &#177; 11.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 57.9 &#177; 2.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.5 &#215; 10<sup>5</sup></td></tr>
###xml 1107 1113 1027 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink">96-104</sup>
###xml 1095 1113 1019 1033 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td>
###xml 1113 1118 1033 1038 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPN </td>
###xml 1118 1134 1038 1052 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 448.9 &#177; 43.8 </td>
###xml 1134 1147 1052 1063 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.9 &#177; 0.1 </td>
###xml 1156 1157 1072 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1147 1157 1063 1073 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 6.5 &#215; 10<sup>3</sup></td>
###xml 1095 1157 1019 1073 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 448.9 &#177; 43.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.9 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6.5 &#215; 10<sup>3</sup></td></tr>
###xml 1168 1175 1081 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125-133</sup>
###xml 1157 1175 1073 1088 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td>
###xml 1175 1180 1088 1093 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPN </td>
###xml 1180 1194 1093 1105 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 53.2 &#177; 4.9 </td>
###xml 1194 1209 1105 1118 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 109.1 &#177; 3.6 </td>
###xml 1218 1219 1127 1128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1209 1219 1118 1128 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#215; 10<sup>6</sup></td>
###xml 1157 1219 1073 1128 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 53.2 &#177; 4.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 109.1 &#177; 3.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#215; 10<sup>6</sup></td></tr>
###xml 1231 1236 1136 1141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">54-62</sup>
###xml 1219 1236 1128 1141 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td>
###xml 1236 1241 1141 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPN </td>
###xml 1241 1257 1146 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 657.6 &#177; 20.5 </td>
###xml 1257 1270 1160 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 3.5 &#177; 0.1 </td>
###xml 1279 1280 1180 1181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1270 1280 1171 1181 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 5.3 &#215; 10<sup>3</sup></td>
###xml 1219 1280 1128 1181 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 657.6 &#177; 20.5 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.5 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.3 &#215; 10<sup>3</sup></td></tr>
###xml 1292 1297 1189 1194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">77-85</sup>
###xml 1280 1297 1181 1194 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td>
###xml 1297 1302 1194 1199 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> CPN </td>
###xml 1302 1320 1199 1215 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 3727.0 &#177; 408.6 </td>
###xml 1320 1334 1215 1227 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 11.8 &#177; 0.8 </td>
###xml 1343 1344 1236 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1334 1344 1227 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 3.2 &#215; 10<sup>3</sup></td>
###xml 1280 1344 1181 1237 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 3727.0 &#177; 408.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 11.8 &#177; 0.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.2 &#215; 10<sup>3</sup></td></tr>
###xml 407 1344 395 1237 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>s<sup>-1</sup></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic><sc>m</sc><sup>-1</sup> s<sup>-1</sup></italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 122.8 &#177; 6.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.7 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.2 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 70.6 &#177; 4.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 19.7 &#177; 4.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.8 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 219.0 &#177; 16.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 29.5 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.3 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 35.9 &#177; 6.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 8.4 &#177; 0.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.3 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 361.4 &#177; 69.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.2 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 14.3 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.6 &#177; 0.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.5 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 34.0 &#177; 4.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.6 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.6 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 238.9 &#177; 24.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.9 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.5 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 170.6 &#177; 27.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 80.35 &#177; 5.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.7 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 302.7 &#177; 29.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.1 &#177; 0.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.0 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 602.2 &#177; 74.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.3 &#177; 0.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 77.1 &#177; 11.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 57.9 &#177; 2.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.5 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 448.9 &#177; 43.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.9 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6.5 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 53.2 &#177; 4.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 109.1 &#177; 3.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#215; 10<sup>6</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 657.6 &#177; 20.5 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.5 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.3 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 3727.0 &#177; 408.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 11.8 &#177; 0.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.2 &#215; 10<sup>3</sup></td></tr></tbody>
###xml 379 1344 367 1237 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Substrate</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Enzyme</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic></bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>s<sup>-1</sup></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic><sc>m</sc><sup>-1</sup> s<sup>-1</sup></italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 122.8 &#177; 6.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.7 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.2 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 70.6 &#177; 4.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 19.7 &#177; 4.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.8 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 219.0 &#177; 16.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 29.5 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.3 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 35.9 &#177; 6.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 8.4 &#177; 0.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.3 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 361.4 &#177; 69.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.2 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 14.3 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.6 &#177; 0.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.5 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 34.0 &#177; 4.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.6 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.6 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 238.9 &#177; 24.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.9 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.5 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 170.6 &#177; 27.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 80.35 &#177; 5.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.7 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 302.7 &#177; 29.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.1 &#177; 0.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.0 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 602.2 &#177; 74.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.3 &#177; 0.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 77.1 &#177; 11.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 57.9 &#177; 2.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.5 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 448.9 &#177; 43.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.9 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6.5 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 53.2 &#177; 4.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 109.1 &#177; 3.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#215; 10<sup>6</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 657.6 &#177; 20.5 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.5 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.3 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 3727.0 &#177; 408.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 11.8 &#177; 0.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.2 &#215; 10<sup>3</sup></td></tr></tbody></table>
###xml 0 1344 0 1237 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl1"><label>TABLE 1</label><caption><p textid="32"><bold>Hydrolysis of chemerin 10-mer peptides by CPB and CPN</bold></p><p textid="33">Chemerin peptides ranging from 20 to 320 &#956;<sc>m</sc> were digested with CPB or CPN as described under &#8220;Experimental Procedures.&#8221; The values for <italic>K<sub>m</sub>, k</italic><sub>cat</sub>, and <italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic> were compared with those obtained from CPB and CPN cleavages of peptides derived from bradykinin, C5a, C3a, and fibrinopeptides (FB) &#945;, &#946;, and &#947; (<xref ref-type="bibr" rid="ref15">15</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Substrate</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Enzyme</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>m</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>k</italic><sub>cat</sub>/<italic>K<sub>m</sub></italic></bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>s<sup>-1</sup></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic><sc>m</sc><sup>-1</sup> s<sup>-1</sup></italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 122.8 &#177; 6.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.7 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.2 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 70.6 &#177; 4.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 19.7 &#177; 4.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.8 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 219.0 &#177; 16.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 29.5 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.3 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 35.9 &#177; 6.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 8.4 &#177; 0.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.3 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 361.4 &#177; 69.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.2 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 14.3 &#177; 0.7 </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.6 &#177; 0.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.5 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 34.0 &#177; 4.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.6 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.6 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPB </td><td colspan="1" rowspan="1" align="center" valign="top"> 238.9 &#177; 24.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.9 &#177; 0.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.5 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Chemerin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 170.6 &#177; 27.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 80.35 &#177; 5.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 4.7 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Bradykinin </td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 302.7 &#177; 29.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.1 &#177; 0.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.0 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C5a<sup>66-74</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 602.2 &#177; 74.3 </td><td colspan="1" rowspan="1" align="center" valign="top"> 9.3 &#177; 0.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 &#215; 10<sup>4</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3a<sup>69-77</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 77.1 &#177; 11.2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 57.9 &#177; 2.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.5 &#215; 10<sup>5</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#945;-Arg<sup>96-104</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 448.9 &#177; 43.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.9 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6.5 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#946;-Lys<sup>125-133</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 53.2 &#177; 4.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 109.1 &#177; 3.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.1 &#215; 10<sup>6</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>54-62</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 657.6 &#177; 20.5 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.5 &#177; 0.1 </td><td colspan="1" rowspan="1" align="center" valign="top"> 5.3 &#215; 10<sup>3</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FB&#947;-Lys<sup>77-85</sup></td><td colspan="1" rowspan="1" align="center" valign="top"> CPN </td><td colspan="1" rowspan="1" align="center" valign="top"> 3727.0 &#177; 408.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 11.8 &#177; 0.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 3.2 &#215; 10<sup>3</sup></td></tr></tbody></table></table-wrap>
###xml 408 412 <span type="species:ncbi:41568">mums</span>
TABLE 1Hydrolysis of chemerin 10-mer peptides by CPB and CPNChemerin peptides ranging from 20 to 320 mum were digested with CPB or CPN as described under "Experimental Procedures." The values for Km, kcat, and kcat/Km were compared with those obtained from CPB and CPN cleavages of peptides derived from bradykinin, C5a, C3a, and fibrinopeptides (FB) alpha, beta, and gamma (15).SubstrateEnzymeKmkcatkcat/Km mums-1m-1 s-1 Chemerin  CPB  122.8 +/- 6.4  2.7 +/- 0.1  2.2 x 104 Bradykinin  CPB  70.6 +/- 4.8  19.7 +/- 4.8  2.8 x 105 C5a66-74 CPB  219.0 +/- 16.2  29.5 +/- 0.7  1.3 x 105 C3a69-77 CPB  35.9 +/- 6.6  8.4 +/- 0.6  2.3 x 105 FBalpha-Arg96-104 CPB  361.4 +/- 69.2  1.5 +/- 0.1  4.2 x 103 FBbeta-Lys125-133 CPB  14.3 +/- 0.7  13.6 +/- 0.2  9.5 x 105 FBgamma-Lys54-62 CPB  34.0 +/- 4.1  2.6 +/- 0.1  7.6 x 104 FBgamma-Lys77-85 CPB  238.9 +/- 24.2  5.9 +/- 0.3  2.5 x 104 Chemerin  CPN  170.6 +/- 27.2  80.35 +/- 5.0  4.7 x 105 Bradykinin  CPN  302.7 +/- 29.1  9.1 +/- 0.2  3.0 x 104 C5a66-74 CPN  602.2 +/- 74.3  9.3 +/- 0.4  1.5 x 104 C3a69-77 CPN  77.1 +/- 11.2  57.9 +/- 2.1  7.5 x 105 FBalpha-Arg96-104 CPN  448.9 +/- 43.8  2.9 +/- 0.1  6.5 x 103 FBbeta-Lys125-133 CPN  53.2 +/- 4.9  109.1 +/- 3.6  2.1 x 106 FBgamma-Lys54-62 CPN  657.6 +/- 20.5  3.5 +/- 0.1  5.3 x 103 FBgamma-Lys77-85 CPN  3727.0 +/- 408.6  11.8 +/- 0.8  3.2 x 103
###end p 31
###begin p 32
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hydrolysis of chemerin 10-mer peptides by CPB and CPN</bold>
Hydrolysis of chemerin 10-mer peptides by CPB and CPN
###end p 32
###begin p 33
###xml 43 44 42 43 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 137 138 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 136 141 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub>, k</italic>
###xml 141 144 140 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 150 151 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 151 154 150 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cat</sub>
###xml 156 157 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 155 157 154 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 315 317 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
Chemerin peptides ranging from 20 to 320 mum were digested with CPB or CPN as described under "Experimental Procedures." The values for Km, kcat, and kcat/Km were compared with those obtained from CPB and CPN cleavages of peptides derived from bradykinin, C5a, C3a, and fibrinopeptides (FB) alpha, beta, and gamma (15).
###end p 33
###begin p 34
###xml 0 122 0 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sequential Proteolysis of Prochemerin 15-mer Peptide by Plasmin and Carboxypeptidases Synergistically Enhances Bioactivity</italic>
###xml 187 194 187 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">149&#8211;163</sup>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 222 229 222 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 807 808 795 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 801 808 789 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
Sequential Proteolysis of Prochemerin 15-mer Peptide by Plasmin and Carboxypeptidases Synergistically Enhances Bioactivity-The synthetic chemerin 15-mer peptide, YFPGQFAFSKALPRS (chemerin149-163) is chemotactically inert (Fig. 2A). Treatment of the 15-mer with CPN or CPB alone had no effect on chemerin bioactivity. However, sequential treatment of the 15-mer with plasmin and CPN or CPB dramatically enhanced its chemotactic activity. The proteolytic products were evaluated by HPLC to determine processing sites. Plasmin first cleaved the 15-mer (retention time, 29.96 min) to 10-mer (retention time: 25.3 min; the peak with the retention time at 12.4 min is the carboxyl-terminal plasmin-generated 5-mer). CPN or CPB then converted the 10-mer to the 9-mer (retention time, approximately27.6 min) (Fig. 2B).
###end p 34
###begin p 35
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 122 9 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequential proteolysis of prochemerin 15-mer by plasmin and carboxypeptidases generates bioactive chemerin 9-mer.</bold>
###xml 122 133 122 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A, in vitro</italic>
###xml 269 270 268 269 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 304 305 302 303 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 382 383 373 374 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 402 403 393 394 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 518 519 503 504 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 621 622 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 633 634 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 644 645 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 9 732 9 715 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><bold>Sequential proteolysis of prochemerin 15-mer by plasmin and carboxypeptidases generates bioactive chemerin 9-mer.</bold><italic>A, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to prochemerin 15-mer in the presence or absence of plasmin, CPB or CPN. 15-mer peptide (1 &#956;<sc>m</sc>) was incubated with plasmin (1 &#956;<sc>m</sc>) at 37 &#176;C for 30 min; the reaction was then terminated by PPACK (10 &#956;<sc>m</sc>). CPN or CPB (30 n<sc>m</sc>) was added and incubated for 30 min at 37 &#176;C. The final concentration of 15-mer used for the assay was 100 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005. <italic>B</italic>, HPLC analysis of prochemerin 15-mer cleavage by plasmin, plasmin/CPN, or plasmin/CPB.</p>
###xml 9 732 9 715 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36"><bold>Sequential proteolysis of prochemerin 15-mer by plasmin and carboxypeptidases generates bioactive chemerin 9-mer.</bold><italic>A, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to prochemerin 15-mer in the presence or absence of plasmin, CPB or CPN. 15-mer peptide (1 &#956;<sc>m</sc>) was incubated with plasmin (1 &#956;<sc>m</sc>) at 37 &#176;C for 30 min; the reaction was then terminated by PPACK (10 &#956;<sc>m</sc>). CPN or CPB (30 n<sc>m</sc>) was added and incubated for 30 min at 37 &#176;C. The final concentration of 15-mer used for the assay was 100 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005. <italic>B</italic>, HPLC analysis of prochemerin 15-mer cleavage by plasmin, plasmin/CPN, or plasmin/CPB.</p></caption>
###xml 732 732 715 715 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0070963680002"/>
###xml 0 732 0 715 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="36"><bold>Sequential proteolysis of prochemerin 15-mer by plasmin and carboxypeptidases generates bioactive chemerin 9-mer.</bold><italic>A, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to prochemerin 15-mer in the presence or absence of plasmin, CPB or CPN. 15-mer peptide (1 &#956;<sc>m</sc>) was incubated with plasmin (1 &#956;<sc>m</sc>) at 37 &#176;C for 30 min; the reaction was then terminated by PPACK (10 &#956;<sc>m</sc>). CPN or CPB (30 n<sc>m</sc>) was added and incubated for 30 min at 37 &#176;C. The final concentration of 15-mer used for the assay was 100 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005. <italic>B</italic>, HPLC analysis of prochemerin 15-mer cleavage by plasmin, plasmin/CPN, or plasmin/CPB.</p></caption><graphic xlink:href="zbc0070963680002"/></fig>
FIGURE 2.Sequential proteolysis of prochemerin 15-mer by plasmin and carboxypeptidases generates bioactive chemerin 9-mer.A, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to prochemerin 15-mer in the presence or absence of plasmin, CPB or CPN. 15-mer peptide (1 mum) was incubated with plasmin (1 mum) at 37 degreesC for 30 min; the reaction was then terminated by PPACK (10 mum). CPN or CPB (30 nm) was added and incubated for 30 min at 37 degreesC. The final concentration of 15-mer used for the assay was 100 nm. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). **, p < 0.005. B, HPLC analysis of prochemerin 15-mer cleavage by plasmin, plasmin/CPN, or plasmin/CPB.
###end p 35
###begin p 36
###xml 0 113 0 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequential proteolysis of prochemerin 15-mer by plasmin and carboxypeptidases generates bioactive chemerin 9-mer.</bold>
###xml 113 124 113 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A, in vitro</italic>
###xml 260 261 259 260 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 295 296 293 294 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 373 374 364 365 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 393 394 384 385 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 509 510 494 495 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 612 613 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 624 625 607 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 635 636 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
Sequential proteolysis of prochemerin 15-mer by plasmin and carboxypeptidases generates bioactive chemerin 9-mer.A, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to prochemerin 15-mer in the presence or absence of plasmin, CPB or CPN. 15-mer peptide (1 mum) was incubated with plasmin (1 mum) at 37 degreesC for 30 min; the reaction was then terminated by PPACK (10 mum). CPN or CPB (30 nm) was added and incubated for 30 min at 37 degreesC. The final concentration of 15-mer used for the assay was 100 nm. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). **, p < 0.005. B, HPLC analysis of prochemerin 15-mer cleavage by plasmin, plasmin/CPN, or plasmin/CPB.
###end p 36
###begin p 37
###xml 0 107 0 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sequential Proteolysis of Prochemerin by Plasmin and Carboxypeptidases Synergistically Enhances Bioactivity</italic>
###xml 281 282 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 387 388 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 381 388 381 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 519 520 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 513 520 513 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 625 626 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 619 626 619 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 686 687 686 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Sequential Proteolysis of Prochemerin by Plasmin and Carboxypeptidases Synergistically Enhances Bioactivity-We next asked whether sequential treatment of chemotactically inert concentrations of prochemerin by plasmin and CPN or CPB could activate the attractant and generate the NH2-YFPGQFAFS-COOH form. Plasmin alone cleaved prochemerin and increased its chemotactic bioactivity (Fig. 3A). Sequential treatment of prochemerin with plasmin and CPN or CPB, however, dramatically enhanced its chemotactic activity (Fig. 3B). The proteolytic products were evaluated by mass spectrometry to determine the processing sites (Fig. 3C). Plasmin first cleaved prochemerin (17730.12 Da) to the NH2-YFPGQFAFSK-COOH form (16301.13 Da), and then CPN or CPB removed the terminal lysine to generate a desLys form (16156.22/16156.36 Da) with enhanced activity. Prochemerin treated with CPN and CPB alone did not induce CMKLR1-mediated chemotaxis (data not shown).
###end p 37
###begin p 38
###xml 0 91 0 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Endogenous Plasma CPN Is Critical for the Increased Activity of Plasmin-cleaved Prochemerin</italic>
###xml 353 354 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 347 354 347 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 428 435 428 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 656 657 656 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 650 657 650 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
Endogenous Plasma CPN Is Critical for the Increased Activity of Plasmin-cleaved Prochemerin-Prochemerin was incubated with plasmin and then treated with PPACK to inhibit serine protease activity. Plasmin-treated prochemerin was added to normal platelet-poor plasma (PPP) as well as PPP treated with MGTA, a specific inhibitor for CPN but not CPB (Fig. 4A). Plasmin-cleaved prochemerin did not induce CMKLR1-mediated chemotaxis (Fig. 4B). Incubation with PPP, however, dramatically increased its bioactivity, which was inhibited by MGTA, indicating that endogenous plasma CPN is critical for activating low concentrations of plasmin-cleaved chemerin (Fig. 4B).
###end p 38
###begin p 39
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 124 9 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequential proteolysis of prochemerin protein by plasmin and carboxypeptidases generates a potent chemerin isoform.</bold>
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 225 236 225 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, in vitro</italic>
###xml 445 446 445 446 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 548 549 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 560 561 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 571 572 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 728 729 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 734 735 732 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 745 746 742 743 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 752 753 749 750 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 763 764 760 761 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 9 779 9 776 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><bold>Sequential proteolysis of prochemerin protein by plasmin and carboxypeptidases generates a potent chemerin isoform.</bold><italic>A</italic>, dose-response curve of prochemerin activation by plasmin assayed by CMKLR1/L1.2 cells chemotaxis. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to full-length recombinant prochemerin protein, prochemerin/plasmin, prochemerin/plasmin/CPN, or CPB. The final concentration of chemerin used for the assay was 0.5 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005. <italic>C</italic>, MALDI-TOF mass spectrometry analysis of prochemerin cleavage by plasmin, plasmin/CPN, or plasmin/CPB. The concentrations of plasmin, CPN, and CPB used in <italic>B</italic> and <italic>C</italic> were 1 &#956;<sc>m</sc>, 30 n<sc>m</sc>, and 30 n<sc>m</sc>, respectively.</p>
###xml 9 779 9 776 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40"><bold>Sequential proteolysis of prochemerin protein by plasmin and carboxypeptidases generates a potent chemerin isoform.</bold><italic>A</italic>, dose-response curve of prochemerin activation by plasmin assayed by CMKLR1/L1.2 cells chemotaxis. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to full-length recombinant prochemerin protein, prochemerin/plasmin, prochemerin/plasmin/CPN, or CPB. The final concentration of chemerin used for the assay was 0.5 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005. <italic>C</italic>, MALDI-TOF mass spectrometry analysis of prochemerin cleavage by plasmin, plasmin/CPN, or plasmin/CPB. The concentrations of plasmin, CPN, and CPB used in <italic>B</italic> and <italic>C</italic> were 1 &#956;<sc>m</sc>, 30 n<sc>m</sc>, and 30 n<sc>m</sc>, respectively.</p></caption>
###xml 779 779 776 776 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0070963680003"/>
###xml 0 779 0 776 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="40"><bold>Sequential proteolysis of prochemerin protein by plasmin and carboxypeptidases generates a potent chemerin isoform.</bold><italic>A</italic>, dose-response curve of prochemerin activation by plasmin assayed by CMKLR1/L1.2 cells chemotaxis. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to full-length recombinant prochemerin protein, prochemerin/plasmin, prochemerin/plasmin/CPN, or CPB. The final concentration of chemerin used for the assay was 0.5 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005. <italic>C</italic>, MALDI-TOF mass spectrometry analysis of prochemerin cleavage by plasmin, plasmin/CPN, or plasmin/CPB. The concentrations of plasmin, CPN, and CPB used in <italic>B</italic> and <italic>C</italic> were 1 &#956;<sc>m</sc>, 30 n<sc>m</sc>, and 30 n<sc>m</sc>, respectively.</p></caption><graphic xlink:href="zbc0070963680003"/></fig>
FIGURE 3.Sequential proteolysis of prochemerin protein by plasmin and carboxypeptidases generates a potent chemerin isoform.A, dose-response curve of prochemerin activation by plasmin assayed by CMKLR1/L1.2 cells chemotaxis. B, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to full-length recombinant prochemerin protein, prochemerin/plasmin, prochemerin/plasmin/CPN, or CPB. The final concentration of chemerin used for the assay was 0.5 nm. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). **, p < 0.005. C, MALDI-TOF mass spectrometry analysis of prochemerin cleavage by plasmin, plasmin/CPN, or plasmin/CPB. The concentrations of plasmin, CPN, and CPB used in B and C were 1 mum, 30 nm, and 30 nm, respectively.
###end p 39
###begin p 40
###xml 0 115 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequential proteolysis of prochemerin protein by plasmin and carboxypeptidases generates a potent chemerin isoform.</bold>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 216 227 216 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, in vitro</italic>
###xml 436 437 436 437 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 539 540 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 551 552 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 562 563 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 719 720 717 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 725 726 723 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 736 737 733 734 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 743 744 740 741 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 754 755 751 752 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Sequential proteolysis of prochemerin protein by plasmin and carboxypeptidases generates a potent chemerin isoform.A, dose-response curve of prochemerin activation by plasmin assayed by CMKLR1/L1.2 cells chemotaxis. B, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to full-length recombinant prochemerin protein, prochemerin/plasmin, prochemerin/plasmin/CPN, or CPB. The final concentration of chemerin used for the assay was 0.5 nm. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). **, p < 0.005. C, MALDI-TOF mass spectrometry analysis of prochemerin cleavage by plasmin, plasmin/CPN, or plasmin/CPB. The concentrations of plasmin, CPN, and CPB used in B and C were 1 mum, 30 nm, and 30 nm, respectively.
###end p 40
###begin p 41
###xml 0 38 0 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Identification of Chemerin in Platelet</italic>
###xml 381 387 369 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">21&#8211;157</sup>
###xml 395 396 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 389 396 377 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 520 522 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 746 747 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 740 747 728 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>B</italic></xref>
Identification of Chemerin in Platelet-Platelets store various coagulation proteins as well as inflammatory factors. To determine whether platelets are also involved in chemerin expression, Western blot analysis and RT-PCR were performed. Chemerin was detected by Western blot in total platelet lysates, with a molecular mass of approximately16 kDa, similar to recombinant chemerin21-157 (Fig. 5A). Although platelets are anuclear, long lived mRNAs are present in the cytosol, including messages for certain chemokines (26). We detected chemerin mRNA in platelets by RT-PCR. An expected 229-bp PCR product was amplified from cDNAs of platelets, as well as from Hep3B (hepatic carcinoma cell line) and MEG-01 (megakaryotic cell line) cells (Fig. 5B). Identity of the amplified chemerin PCR product was confirmed by direct sequencing.
###end p 41
###begin p 42
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 9 88 9 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Endogenous plasma CPN increases the bioactivity of plasmin-cleaved prochemerin.</bold>
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 175 186 174 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, in vitro</italic>
###xml 386 387 384 385 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 432 433 429 430 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 506 507 496 497 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 624 625 614 615 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 727 728 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 739 740 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 749 9 737 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="43"><bold>Endogenous plasma CPN increases the bioactivity of plasmin-cleaved prochemerin.</bold><italic>A</italic>, MGTA specifically inhibits CPN but not CPB. 1 &#956;g/ml of either CPN or CPB was used. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to plasmin-treated full-length recombinant prochemerin protein, prochemerin/plasmin/PPP, or prochemerin/plasmin/PPP treated with the CPN inhibitor MGTA (5 &#956;<sc>m</sc>). Prochemerin was treated with plasmin (1 &#956;<sc>m</sc>) at 37 &#176;C for 30 min, and the reaction was stopped by PPACK (10 &#956;<sc>m</sc>). PPP or PPP/MGTA was added to plasmin cleaved prochemerin. The final concentration of treated prochemerin was 0.2 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005.</p>
###xml 9 749 9 737 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43"><bold>Endogenous plasma CPN increases the bioactivity of plasmin-cleaved prochemerin.</bold><italic>A</italic>, MGTA specifically inhibits CPN but not CPB. 1 &#956;g/ml of either CPN or CPB was used. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to plasmin-treated full-length recombinant prochemerin protein, prochemerin/plasmin/PPP, or prochemerin/plasmin/PPP treated with the CPN inhibitor MGTA (5 &#956;<sc>m</sc>). Prochemerin was treated with plasmin (1 &#956;<sc>m</sc>) at 37 &#176;C for 30 min, and the reaction was stopped by PPACK (10 &#956;<sc>m</sc>). PPP or PPP/MGTA was added to plasmin cleaved prochemerin. The final concentration of treated prochemerin was 0.2 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005.</p></caption>
###xml 749 749 737 737 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0070963680004"/>
###xml 0 749 0 737 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="43"><bold>Endogenous plasma CPN increases the bioactivity of plasmin-cleaved prochemerin.</bold><italic>A</italic>, MGTA specifically inhibits CPN but not CPB. 1 &#956;g/ml of either CPN or CPB was used. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to plasmin-treated full-length recombinant prochemerin protein, prochemerin/plasmin/PPP, or prochemerin/plasmin/PPP treated with the CPN inhibitor MGTA (5 &#956;<sc>m</sc>). Prochemerin was treated with plasmin (1 &#956;<sc>m</sc>) at 37 &#176;C for 30 min, and the reaction was stopped by PPACK (10 &#956;<sc>m</sc>). PPP or PPP/MGTA was added to plasmin cleaved prochemerin. The final concentration of treated prochemerin was 0.2 n<sc>m</sc>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005.</p></caption><graphic xlink:href="zbc0070963680004"/></fig>
FIGURE 4.Endogenous plasma CPN increases the bioactivity of plasmin-cleaved prochemerin.A, MGTA specifically inhibits CPN but not CPB. 1 mug/ml of either CPN or CPB was used. B, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to plasmin-treated full-length recombinant prochemerin protein, prochemerin/plasmin/PPP, or prochemerin/plasmin/PPP treated with the CPN inhibitor MGTA (5 mum). Prochemerin was treated with plasmin (1 mum) at 37 degreesC for 30 min, and the reaction was stopped by PPACK (10 mum). PPP or PPP/MGTA was added to plasmin cleaved prochemerin. The final concentration of treated prochemerin was 0.2 nm. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). **, p < 0.005.
###end p 42
###begin p 43
###xml 0 79 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Endogenous plasma CPN increases the bioactivity of plasmin-cleaved prochemerin.</bold>
###xml 79 80 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 166 177 165 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, in vitro</italic>
###xml 377 378 375 376 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 423 424 420 421 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 497 498 487 488 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 615 616 605 606 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 718 719 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 730 731 718 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Endogenous plasma CPN increases the bioactivity of plasmin-cleaved prochemerin.A, MGTA specifically inhibits CPN but not CPB. 1 mug/ml of either CPN or CPB was used. B, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to plasmin-treated full-length recombinant prochemerin protein, prochemerin/plasmin/PPP, or prochemerin/plasmin/PPP treated with the CPN inhibitor MGTA (5 mum). Prochemerin was treated with plasmin (1 mum) at 37 degreesC for 30 min, and the reaction was stopped by PPACK (10 mum). PPP or PPP/MGTA was added to plasmin cleaved prochemerin. The final concentration of treated prochemerin was 0.2 nm. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). **, p < 0.005.
###end p 43
###begin p 44
###xml 0 42 0 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Platelets Release Chemerin upon Activation</italic>
###xml 221 222 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 239 240 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 233 240 229 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 339 340 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 333 340 329 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 472 473 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 916 917 912 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 910 917 906 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 1034 1035 1030 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1028 1035 1024 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>D</italic></xref>
Platelets Release Chemerin upon Activation-As quantified by ELISA, the concentration of chemerin in PRP was 48 +/- 1.1 ng/ml. The addition of thrombin (5 units/ml) to PRP increased the chemerin level to 78 +/- 0.7 ng/ml (p < 0.005) (Fig. 6A). The addition of thrombin to PPP, on the other hand, had no effect on chemerin activities (Fig. 6B). Thrombin itself did not induce the chemotaxis of CMKLR1-transfected cells, and thrombin does not cleave and activate prochemein (8). Thus we conclude that the increased chemerin bioactivity in thrombin-treated PRP was not due to proteolysis of circulating plasma prochemerin by thrombin but rather was dependent on the release of chemerin from platelets following thrombin activation. Furthermore, platelet-activating agonists such as thrombin receptor-activating peptide, collagen, and, to a lesser extent, ADP induced the release of chemerin from washed platelets (Fig. 6C), which corresponded with an increase in chemerin bioactivity as determined by CMKLR1 transfectant migration (Fig. 6D).
###end p 44
###begin p 45
###xml 170 176 170 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">21&#8211;157</sup>
###xml 429 435 429 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">21&#8211;157</sup>
###xml 443 444 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 437 444 437 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7<italic>A</italic></xref>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 600 607 600 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7<italic>B</italic></xref>
###xml 1059 1060 1055 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1130 1132 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 1267 1268 1263 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 1386 1387 1382 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1380 1387 1376 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7<italic>C</italic></xref>
###xml 1489 1490 1485 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1483 1490 1479 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7<italic>C</italic></xref>
We next investigated whether the chemerin released from activated platelets is a prochemerin form or an active isoform. The same amount of prochemerin and active chemerin21-157 were used as controls for platelet-derived chemerin (as quantified by ELISA) in transwell assays using CMKLR1/L1.2 transfectants. Chemerin activity released from activated platelets is higher than prochemerin but substantially less active than chemerin21-157 (Fig. 7A). The specific response of platelet-derived chemerin to CMKLR1 transfectants was confirmed in the chemotaxis assay using nontransfected cells as controls (Fig. 7B). This suggested that platelets might release chemerin in a partially active form, or platelet-derived chemerin is a mixture of different forms of chemerin, which probably could undergo further proteolysis to fully express its biological activities. With the addition of plasmin/CPB or plasmin/CPN to platelet releasates, no enhanced chemerin activities were observed, which is likely due to the presence of various plasmin inhibitors, including alpha2-antiplasmin, which is known to be released from activated platelets (27) (data not shown). When platelet-derived chemerins were partially purified by heparin-agarose chromatography as previously described (8), a significantly increased chemerin activity was detected after adding plasmin, plasmin/CPB, and plasmin/CPN (Fig. 7C). Interestingly, chemerin activity was also enhanced even in the presence of CPN or CPB alone (Fig. 7C), indicating that at least a portion of the chemerins released from activated platelets has been already cleaved to a form that is accessible to CPN or CPB cleavage.
###end p 45
###begin p 46
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 53 9 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Platelets contain chemerin mRNA and protein.</bold>
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 9 186 9 186 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47"><bold>Platelets contain chemerin mRNA and protein.</bold><italic>A</italic>, Western blot analysis of chemerin in platelet lysates. <italic>B</italic>, RT-PCR analysis of chemerin message in various cell lines and platelets.</p>
###xml 9 186 9 186 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47"><bold>Platelets contain chemerin mRNA and protein.</bold><italic>A</italic>, Western blot analysis of chemerin in platelet lysates. <italic>B</italic>, RT-PCR analysis of chemerin message in various cell lines and platelets.</p></caption>
###xml 186 186 186 186 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0070963680005"/>
###xml 0 186 0 186 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="47"><bold>Platelets contain chemerin mRNA and protein.</bold><italic>A</italic>, Western blot analysis of chemerin in platelet lysates. <italic>B</italic>, RT-PCR analysis of chemerin message in various cell lines and platelets.</p></caption><graphic xlink:href="zbc0070963680005"/></fig>
FIGURE 5.Platelets contain chemerin mRNA and protein.A, Western blot analysis of chemerin in platelet lysates. B, RT-PCR analysis of chemerin message in various cell lines and platelets.
###end p 46
###begin p 47
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Platelets contain chemerin mRNA and protein.</bold>
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
Platelets contain chemerin mRNA and protein.A, Western blot analysis of chemerin in platelet lysates. B, RT-PCR analysis of chemerin message in various cell lines and platelets.
###end p 47
###begin title 48
DISCUSSION
###end title 48
###begin p 49
###xml 268 275 268 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
###xml 318 326 318 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 775 776 775 776 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1080 1087 1080 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
In this study, we report that plasma-derived CPN and CPB substantially up-regulated the bioactivity of plasmin-cleaved prochemerin via the removal of the carboxyl-terminal lysine residue, adding a novel mechanism to prochemerin processing and activation by proteases (Table 2). We demonstrated this in three different in vitro scenarios: 1) CPN and CPB removed the carboxyl-terminal lysine from a 10-mer chemerin peptide and converted it to a bioactive 9-mer; 2) plasmin cleaved prochemerin 15-mer to 10-mer, which was subsequently converted to the bioactive 9-mer by CPN or CPB; and 3) sequential proteolysis of recombinant prochemerin protein by plasmin followed by CPN or CPB generated a chemerin isoform with potent chemoattractant activity (carboxyl-terminal sequence NH2-YFPGQFAFS-COOH). These data show that CPN and CPB generate a highly active "desLys" form of plasmin-cleaved chemerin. Interestingly, we also found that platelets can regulate chemerin bioactivity by storing and releasing it upon stimulation. We have therefore identified additional circulating factors (Table 2) that contribute to the regulation of chemerin bioactivity and further link the processes of blood coagulation/fibrinolysis with mediators that regulate leukocyte migration.
###end p 49
###begin p 50
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 2</label>
###xml 7 49 7 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Prochemerin cleavages by various proteases</bold>
###xml 7 49 7 49 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51"><bold>Prochemerin cleavages by various proteases</bold></p>
###xml 49 134 49 134 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">Shown is a summary of prochemerin cleavages by various proteases. ND, not determined.</p>
###xml 7 134 7 134 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51"><bold>Prochemerin cleavages by various proteases</bold></p><p textid="52">Shown is a summary of prochemerin cleavages by various proteases. ND, not determined.</p></caption>
###xml 134 142 134 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Protease</bold>
###xml 134 142 134 142 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Protease</bold></th>
###xml 142 161 142 161 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C-terminal sequence</bold>
###xml 142 161 142 161 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>C-terminal sequence</bold></th>
###xml 161 177 161 177 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Amino acid order</bold>
###xml 161 177 161 177 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Amino acid order</bold></th>
###xml 134 177 134 177 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold>Protease</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>C-terminal sequence</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Amino acid order</bold></th></tr>
###xml 134 177 134 177 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Protease</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>C-terminal sequence</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Amino acid order</bold></th></tr></thead>
###xml 177 190 177 190 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Unprocessed </td>
###xml 190 210 190 210 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSKALPRS </td>
###xml 210 218 210 218 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-163 </td>
###xml 177 218 177 218 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Unprocessed </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSKALPRS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-163 </td></tr>
###xml 218 231 218 231 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPB </td>
###xml 231 245 231 245 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td>
###xml 245 253 245 253 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td>
###xml 218 253 218 253 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPB </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr>
###xml 253 266 253 266 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPN </td>
###xml 266 280 266 280 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td>
###xml 280 288 280 288 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td>
###xml 253 288 253 288 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPN </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr>
###xml 288 297 288 297 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Plasmin </td>
###xml 297 312 297 312 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td>
###xml 312 320 312 320 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td>
###xml 288 320 288 320 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td></tr>
###xml 320 330 320 330 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Elastase </td>
###xml 330 344 330 344 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td>
###xml 344 352 344 352 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td>
###xml 320 352 320 352 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Elastase </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr>
###xml 352 352 352 352 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 352 364 352 364 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td>
###xml 364 372 364 372 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td>
###xml 352 372 352 372 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td></tr>
###xml 372 372 372 372 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 372 381 372 381 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPG </td>
###xml 381 389 381 389 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-152 </td>
###xml 372 389 372 389 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPG </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-152 </td></tr>
###xml 389 399 389 399 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Tryptase </td>
###xml 399 414 399 414 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td>
###xml 414 422 414 422 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td>
###xml 389 422 389 422 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Tryptase </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td></tr>
###xml 422 422 422 422 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 422 434 422 434 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td>
###xml 434 442 434 442 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td>
###xml 422 442 422 442 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td></tr>
###xml 442 455 442 455 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Cathepsin G </td>
###xml 455 468 455 468 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAF </td>
###xml 468 476 468 476 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-156 </td>
###xml 442 476 442 476 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Cathepsin G </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAF </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-156 </td></tr>
###xml 476 490 476 490 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Staphopain B </td>
###xml 490 504 490 504 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td>
###xml 504 512 504 512 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td>
###xml 476 512 476 512 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Staphopain B </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr>
###xml 512 519 512 519 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FVIIa </td>
###xml 519 523 519 523 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ND </td>
###xml 523 523 523 523 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 512 523 512 523 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FVIIa </td><td colspan="1" rowspan="1" align="left" valign="top"> ND </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 523 530 523 530 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> FXIIa </td>
###xml 530 534 530 534 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> ND </td>
###xml 534 534 534 534 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 523 534 523 534 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> FXIIa </td><td colspan="1" rowspan="1" align="left" valign="top"> ND </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 177 534 177 534 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"> Unprocessed </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSKALPRS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-163 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPB </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPN </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Elastase </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPG </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-152 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tryptase </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Cathepsin G </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAF </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-156 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Staphopain B </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FVIIa </td><td colspan="1" rowspan="1" align="left" valign="top"> ND </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FXIIa </td><td colspan="1" rowspan="1" align="left" valign="top"> ND </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr></tbody>
###xml 134 534 134 534 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Protease</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>C-terminal sequence</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Amino acid order</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> Unprocessed </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSKALPRS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-163 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPB </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPN </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Elastase </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPG </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-152 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tryptase </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Cathepsin G </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAF </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-156 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Staphopain B </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FVIIa </td><td colspan="1" rowspan="1" align="left" valign="top"> ND </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FXIIa </td><td colspan="1" rowspan="1" align="left" valign="top"> ND </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr></tbody></table>
###xml 0 534 0 534 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl2"><label>TABLE 2</label><caption><p textid="51"><bold>Prochemerin cleavages by various proteases</bold></p><p textid="52">Shown is a summary of prochemerin cleavages by various proteases. ND, not determined.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Protease</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>C-terminal sequence</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Amino acid order</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> Unprocessed </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSKALPRS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-163 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPB </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin/CPN </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Plasmin </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Elastase </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPG </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-152 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Tryptase </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFSK </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-158 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFA </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-155 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Cathepsin G </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAF </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-156 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Staphopain B </td><td colspan="1" rowspan="1" align="left" valign="top"> ...YFPGQFAFS </td><td colspan="1" rowspan="1" align="center" valign="top"> 21-157 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FVIIa </td><td colspan="1" rowspan="1" align="left" valign="top"> ND </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> FXIIa </td><td colspan="1" rowspan="1" align="left" valign="top"> ND </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr></tbody></table></table-wrap>
TABLE 2Prochemerin cleavages by various proteasesShown is a summary of prochemerin cleavages by various proteases. ND, not determined.ProteaseC-terminal sequenceAmino acid order Unprocessed  ...YFPGQFAFSKALPRS  21-163  Plasmin/CPB  ...YFPGQFAFS  21-157  Plasmin/CPN  ...YFPGQFAFS  21-157  Plasmin  ...YFPGQFAFSK  21-158  Elastase  ...YFPGQFAFS  21-157  ...YFPGQFA  21-155  ...YFPG  21-152  Tryptase  ...YFPGQFAFSK  21-158  ...YFPGQFA  21-155  Cathepsin G  ...YFPGQFAF  21-156  Staphopain B  ...YFPGQFAFS  21-157  FVIIa  ND  FXIIa  ND 
###end p 50
###begin p 51
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Prochemerin cleavages by various proteases</bold>
Prochemerin cleavages by various proteases
###end p 51
###begin p 52
Shown is a summary of prochemerin cleavages by various proteases. ND, not determined.
###end p 52
###begin p 53
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 9 52 9 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Platelets release chemerin upon activation.</bold>
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 154 165 154 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, in vitro</italic>
###xml 356 357 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 362 363 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 445 446 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 451 459 445 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 503 504 497 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 651 652 638 639 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 714 715 699 700 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 883 884 865 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 895 896 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 905 9 887 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54"><bold>Platelets release chemerin upon activation.</bold><italic>A</italic>, ELISA quantification of total chemerin present in resting and thrombin (5 units/ml) activated PRP. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to PRP, and PRP/thrombin (5 units/ml), PPP, and PPP/thrombin (5 units/ml). Thrombin at 5 units/ml was added to PRP or PPP at 37 &#176;C for 5 min. <italic>C</italic> and <italic>D</italic>, identification of chemerin in washed platelet lysates by Western blot analysis (<italic>C</italic>) or <italic>in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells (<italic>D</italic>). The platelets were treated with the indicated platelet-activating agonists at 37 &#176;C for 3 min: thrombin receptor-activating peptide (20 &#956;<sc>m</sc>), thrombin (5 units/ml), collagen (10 &#956;g/ml), and ADP (10 &#956;<sc>m</sc>). 200 &#956;l of platelet releasates were tested in chemotaxis assays. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005.</p>
###xml 9 905 9 887 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="54"><bold>Platelets release chemerin upon activation.</bold><italic>A</italic>, ELISA quantification of total chemerin present in resting and thrombin (5 units/ml) activated PRP. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to PRP, and PRP/thrombin (5 units/ml), PPP, and PPP/thrombin (5 units/ml). Thrombin at 5 units/ml was added to PRP or PPP at 37 &#176;C for 5 min. <italic>C</italic> and <italic>D</italic>, identification of chemerin in washed platelet lysates by Western blot analysis (<italic>C</italic>) or <italic>in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells (<italic>D</italic>). The platelets were treated with the indicated platelet-activating agonists at 37 &#176;C for 3 min: thrombin receptor-activating peptide (20 &#956;<sc>m</sc>), thrombin (5 units/ml), collagen (10 &#956;g/ml), and ADP (10 &#956;<sc>m</sc>). 200 &#956;l of platelet releasates were tested in chemotaxis assays. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005.</p></caption>
###xml 905 905 887 887 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0070963680006"/>
###xml 0 905 0 887 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="54"><bold>Platelets release chemerin upon activation.</bold><italic>A</italic>, ELISA quantification of total chemerin present in resting and thrombin (5 units/ml) activated PRP. <italic>B, in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells to PRP, and PRP/thrombin (5 units/ml), PPP, and PPP/thrombin (5 units/ml). Thrombin at 5 units/ml was added to PRP or PPP at 37 &#176;C for 5 min. <italic>C</italic> and <italic>D</italic>, identification of chemerin in washed platelet lysates by Western blot analysis (<italic>C</italic>) or <italic>in vitro</italic> transwell chemotaxis of CMKLR1/L1.2 cells (<italic>D</italic>). The platelets were treated with the indicated platelet-activating agonists at 37 &#176;C for 3 min: thrombin receptor-activating peptide (20 &#956;<sc>m</sc>), thrombin (5 units/ml), collagen (10 &#956;g/ml), and ADP (10 &#956;<sc>m</sc>). 200 &#956;l of platelet releasates were tested in chemotaxis assays. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). **, <italic>p</italic> &lt; 0.005.</p></caption><graphic xlink:href="zbc0070963680006"/></fig>
FIGURE 6.Platelets release chemerin upon activation.A, ELISA quantification of total chemerin present in resting and thrombin (5 units/ml) activated PRP. B, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to PRP, and PRP/thrombin (5 units/ml), PPP, and PPP/thrombin (5 units/ml). Thrombin at 5 units/ml was added to PRP or PPP at 37 degreesC for 5 min. C and D, identification of chemerin in washed platelet lysates by Western blot analysis (C) or in vitro transwell chemotaxis of CMKLR1/L1.2 cells (D). The platelets were treated with the indicated platelet-activating agonists at 37 degreesC for 3 min: thrombin receptor-activating peptide (20 mum), thrombin (5 units/ml), collagen (10 mug/ml), and ADP (10 mum). 200 mul of platelet releasates were tested in chemotaxis assays. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). **, p < 0.005.
###end p 53
###begin p 54
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Platelets release chemerin upon activation.</bold>
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 145 156 145 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, in vitro</italic>
###xml 347 348 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 353 354 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 436 437 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 442 450 436 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 494 495 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 642 643 629 630 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 705 706 690 691 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 874 875 856 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 886 887 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Platelets release chemerin upon activation.A, ELISA quantification of total chemerin present in resting and thrombin (5 units/ml) activated PRP. B, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to PRP, and PRP/thrombin (5 units/ml), PPP, and PPP/thrombin (5 units/ml). Thrombin at 5 units/ml was added to PRP or PPP at 37 degreesC for 5 min. C and D, identification of chemerin in washed platelet lysates by Western blot analysis (C) or in vitro transwell chemotaxis of CMKLR1/L1.2 cells (D). The platelets were treated with the indicated platelet-activating agonists at 37 degreesC for 3 min: thrombin receptor-activating peptide (20 mum), thrombin (5 units/ml), collagen (10 mug/ml), and ADP (10 mum). 200 mul of platelet releasates were tested in chemotaxis assays. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). **, p < 0.005.
###end p 54
###begin p 55
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 9 50 9 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Bioactivity of platelet-derived chemerin.</bold>
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 176 182 176 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">21&#8211;157</sup>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 488 489 488 489 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 685 691 685 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 793 794 791 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 804 805 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 818 819 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 828 9 826 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="56"><bold>Bioactivity of platelet-derived chemerin.</bold><italic>A</italic>, comparison of chemotactic activity of chemerin released from activated platelets, prochemerin, and the active form chemerin<sup>21&#8211;157</sup>. <italic>B</italic>, the specific chemotactic response of platelet-derived chemerin to CMKLR1/L1.2 transfectants. <italic>C</italic>, proteolytic regulation of platelet-derived chemerin bioactivity. Platelet-derived chemerin was partially purified by heparin affinity chromatography (<xref ref-type="bibr" rid="ref8">8</xref>). Fractions containing chemerin were eluted with 0.6 <sc>m</sc> of NaCl. The concentration of chemerin was quantitated by ELISA. The conditions of platelet-derived chemerin treated with CPN, CPB, plasmin, plasmin/CPN, or plasmin/CPB were identical to that in <xref rid="fig3" ref-type="fig">Fig. 3</xref>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.005.</p>
###xml 9 828 9 826 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="56"><bold>Bioactivity of platelet-derived chemerin.</bold><italic>A</italic>, comparison of chemotactic activity of chemerin released from activated platelets, prochemerin, and the active form chemerin<sup>21&#8211;157</sup>. <italic>B</italic>, the specific chemotactic response of platelet-derived chemerin to CMKLR1/L1.2 transfectants. <italic>C</italic>, proteolytic regulation of platelet-derived chemerin bioactivity. Platelet-derived chemerin was partially purified by heparin affinity chromatography (<xref ref-type="bibr" rid="ref8">8</xref>). Fractions containing chemerin were eluted with 0.6 <sc>m</sc> of NaCl. The concentration of chemerin was quantitated by ELISA. The conditions of platelet-derived chemerin treated with CPN, CPB, plasmin, plasmin/CPN, or plasmin/CPB were identical to that in <xref rid="fig3" ref-type="fig">Fig. 3</xref>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.005.</p></caption>
###xml 828 828 826 826 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0070963680007"/>
###xml 0 828 0 826 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="56"><bold>Bioactivity of platelet-derived chemerin.</bold><italic>A</italic>, comparison of chemotactic activity of chemerin released from activated platelets, prochemerin, and the active form chemerin<sup>21&#8211;157</sup>. <italic>B</italic>, the specific chemotactic response of platelet-derived chemerin to CMKLR1/L1.2 transfectants. <italic>C</italic>, proteolytic regulation of platelet-derived chemerin bioactivity. Platelet-derived chemerin was partially purified by heparin affinity chromatography (<xref ref-type="bibr" rid="ref8">8</xref>). Fractions containing chemerin were eluted with 0.6 <sc>m</sc> of NaCl. The concentration of chemerin was quantitated by ELISA. The conditions of platelet-derived chemerin treated with CPN, CPB, plasmin, plasmin/CPN, or plasmin/CPB were identical to that in <xref rid="fig3" ref-type="fig">Fig. 3</xref>. The results represent one of three independent experiments and are expressed as the means &#177; S.D. (<italic>n</italic> = 3). *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.005.</p></caption><graphic xlink:href="zbc0070963680007"/></fig>
FIGURE 7.Bioactivity of platelet-derived chemerin.A, comparison of chemotactic activity of chemerin released from activated platelets, prochemerin, and the active form chemerin21-157. B, the specific chemotactic response of platelet-derived chemerin to CMKLR1/L1.2 transfectants. C, proteolytic regulation of platelet-derived chemerin bioactivity. Platelet-derived chemerin was partially purified by heparin affinity chromatography (8). Fractions containing chemerin were eluted with 0.6 m of NaCl. The concentration of chemerin was quantitated by ELISA. The conditions of platelet-derived chemerin treated with CPN, CPB, plasmin, plasmin/CPN, or plasmin/CPB were identical to that in Fig. 3. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). *, p < 0.05; **, p < 0.005.
###end p 55
###begin p 56
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Bioactivity of platelet-derived chemerin.</bold>
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 167 173 167 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">21&#8211;157</sup>
###xml 175 176 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 479 480 479 480 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 676 682 676 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 784 785 782 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 795 796 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 809 810 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Bioactivity of platelet-derived chemerin.A, comparison of chemotactic activity of chemerin released from activated platelets, prochemerin, and the active form chemerin21-157. B, the specific chemotactic response of platelet-derived chemerin to CMKLR1/L1.2 transfectants. C, proteolytic regulation of platelet-derived chemerin bioactivity. Platelet-derived chemerin was partially purified by heparin affinity chromatography (8). Fractions containing chemerin were eluted with 0.6 m of NaCl. The concentration of chemerin was quantitated by ELISA. The conditions of platelet-derived chemerin treated with CPN, CPB, plasmin, plasmin/CPN, or plasmin/CPB were identical to that in Fig. 3. The results represent one of three independent experiments and are expressed as the means +/- S.D. (n = 3). *, p < 0.05; **, p < 0.005.
###end p 56
###begin p 57
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
There is a growing appreciation for the role of extracellular matrix metalloproteinases and serine proteases such as DPP-IV/CD26 and cathepsin G in regulating the activity of chemokines at the post-translational level (1). These enzymes are particularly adept at modifying chemokines to dampen immune responses. For example, CCL7 is a physiological substrate of matrix metalloproteinase 2; matrix metalloproteinase 2-cleaved CCL7 acts as a general chemokine antagonist by binding to but not activating the CC-chemokine receptors-1, -2, and -3, thereby blocking leukocyte recruitment and dampening inflammation (28). Carboxypeptidases CPN and CPB are well known for their ability to inactivate a number of pro-inflammatory mediators including C5a, C3a, bradykinin, and thrombin-cleaved osteopontin (15-17). In the case of plasmin-cleaved prochemerin, CPN/CPB enhances, rather than diminishes, the chemotactic activity of the attractant under the current experimental conditions.
###end p 57
###begin p 58
Cells that are chemerin-responsive include plasmacytoid dendritic cells and macrophages, leukocytes capable of functioning as "immune interpreters"; in the absence of "danger signals," chemerin-recruited plasmacytoid dendritic cell and macrophages may play an immune suppressive role, dampening inflammation through interleukin-10 and transforming growth factor beta secretion and regulating T cell responses. Thus CPN/CPB may serve to dampen inflammatory responses by inactivating anaphylatoxins and by recruiting immune suppressive CMKLR1-positive leukocytes to sites of sterile tissue injury.
###end p 58
###begin p 59
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 175 176 174 175 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 209 217 208 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 432 434 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 436 438 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 614 616 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 702 703 676 677 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 894 901 868 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 276 281 <span type="species:ncbi:9606">human</span>
The regulation of chemerin bioactivity at a site of tissue injury in vivo appears to involve a complex interplay among many enzymatic components. In our study, plasmin at 1 mum efficiently cleaves prochemerin in vitro. Although this is a substantial concentration of plasmin, human platelets have well defined plasminogen binding sites, and these binding sites are further increased by approximately5-fold upon platelet activation (29, 30). In addition, it has been reported that thrombin stimulation specifically induces plasminogen activation that is mediated by endogenous urokinase-type plasminogen activator (31). Thus given the substantial plasma concentration of plasminogen (approximately2.2 mum), it is entirely plausible that prochemerin, upon release from activated platelets, will be efficiently cleaved to chemerin by plasmin generated locally at the site of vascular inflammation in vivo. Plasmin-cleaved prochemerin can be further activated by CPB and CPN. CPB is activated locally by endothelial cell bound thrombin/thrombomodulin and enhances the chemotactic activity of plasmin-cleaved prochemerin via removal of the carboxyl-terminal lysine. At the same time, CPB, in its role as a fibrinolysis inhibitor, blocks plasmin generation, which would diminish the initial activation of circulating prochemerin. Thus CPB may limit the extent of prochemerin activation but enhance the activity of the plasmin-cleaved chemerin that has already been formed. Our study provides further evidence that CPB functions not only as an inhibitor of fibrinolysis, but also as a mediator of inflammatory responses. CPB may be important for local and specific action at sites of tissue damage, whereas constitutively active CPN may regulate its targets systemically.
###end p 59
###begin p 60
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
Platelets are critical in maintaining normal hemostasis (32, 33). Activated platelets release granular proteins that include platelet agonists, adhesive proteins, and chemoattractants at the site of vascular injury, which may play a role in tissue inflammation and remodeling (34-36). In our study, we found that platelets store chemerin. Upon activation, platelets release a mixture of chemerin isoforms with different levels of bioactivity. Some of them would undergo further proteolysis to fully express its biological activity. Our future work will investigate the role of chemerin in platelet biology and tissue remodeling.
###end p 60
###begin p 61
###xml 168 170 168 170 <sc xmlns:xlink="http://www.w3.org/1999/xlink">dl</sc>
###xml 231 232 231 232 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 246 247 246 247 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 255 256 255 256 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 378 381 378 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N,N</italic>
The abbreviations used are: CMKLR1, chemokine-like receptor 1; CPN, carboxypeptidase N; CPB, carboxypeptidase B; TAFI, thrombin-activable fibrinolysis inhibitor; MGTA, dl-2-mercaptomethyl-3 guanidinoethylthiopropanoic acid; PPACK, d-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone; HPLC, high performance liquid chromatography; PRP, platelet-rich plasma; PIPES, piperazine-N,N'-bis(2-ethanesulfonic acid); RT, reverse transcription; ELISA, enzyme-linked immunosorbent assay; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; PPP, platelet-poor plasma.
###end p 61

